RGC Stock — Regencell Bioscience Holdings Ltd

Regencell Bioscience Holdings Ltd (RGC)

Updated October 16, 2026.

RGC is a Stock. Total return is 3370.9% over the past 5.3 years, 3281.1 points ahead of SPY at 89.8%.

Regencell Bioscience Holdings Limited is a Traditional Chinese medicine bioscience company headquartered in Hong Kong that researches, develops, and commercializes TCM treatments for neurocognitive disorders, particularly attention deficit hyperactivity disorder and autism spectrum disorder. The company does not currently have an established distribution schedule. This stock may appeal to investors interested in healthcare innovation and emerging therapeutic approaches.

RGC performance versus SPY

Price and return data through 2026-10-16.

Total return is 3370.9% over the past 5.3 years, 3281.1 points ahead of SPY at 89.8%. Over the past year its total return — price change plus distributions reinvested — is -46.6%. Its deepest 1-year drawdown was 91.0%.

RGC key facts

Asset type

Stock

Asset class

Equity

Inception date

07/16/2021

Distribution frequency

None

Last close

$9.59 (as of 2026-10-16)

Market cap

$4,755,531,166

Average volume

681762.0

Beta

1.166

Payout ratio

0.0%

EPS

$-0.02

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

RGC risks and drawbacks

The deepest 1-year drawdown on record here is 91.0%.

Who may consider RGC — and who may not

It is a weaker fit for investors who need monthly cash flow (RGC does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on RGC

• All tickers starting with R

Tagged: Healthcare.

Frequently asked questions